GZMM and neoplasm: In contrast, AHA treatment in scIgG containing tumors significantly reduced tumor progression in comparison with the isotype antibody treatment control in both xenograft BT474-IdeS tumor model (Fig. 7a) and syngeneic Met1 murine tumor model in MMTV-IdeS transgenic (scIgG-tg) mice (Fig. 7b).